Traditionally, vaccines have helped eradication of several infectious diseases and also
saved millions of lives in the human history. Those prophylactic vaccines have acted through …

Dendritic-cells (DCs) have received considerable attention as potential targets for the
development of anticancer vaccines. DC-based anticancer vaccination relies on patient …

Although increased circulating tumor antigen-specific CD8+ T cells can be achieved by
vaccination or adoptive transfer, tumor progression nonetheless often occurs through …

Immunization with defined tumor antigens is currently limited to a small number of cancers
where candidates for tumor rejection antigens have been identified. In this study we …

It is now possible to grow DC-like cells in culture17-21 and extensive cell membrane
processes that are acquired late the first monoclonal antibodies (MoAbs) 22, 23 that react …

Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting
cells primed to recognize prostatic acid phosphatase, was the first immunotherapy product …

PURPOSE: Provenge (Dendreon Corp, Seattle, WA) is an immunotherapy product
consisting of autologous dendritic cells loaded ex vivo with a recombinant fusion protein …

Human tumors express a number of protein antigens that can be recognized by T cells, thus
providing potential targets for cancer immunotherapy. Dendritic cells (DCs) are rare …

Therapeutic vaccination trials, in which patients with cancer were vaccinated with minimal
CTL peptide in oil-in-water formulations, have met with limited success. Many of these …

Dendritic cells (DC) generated from the peripheral blood mononuclear cells of healthy
individuals or from cancer patients transfected with carcinoembryonic antigen (CEA) mRNA …